Glioblastoma

Vulnerability identified for subtypes of glioblastoma

Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. In a paper published online in the journal Cancer Cell on November 30, University ...

Nov 30, 2017
popularity0 comments 0

Drug combo doesn't lengthen glioblastoma survival

(HealthDay)—In patients with progressive glioblastoma, treatment with lomustine plus bevacizumab does not confer a survival advantage over treatment with lomustine alone, according to a study published online Nov. 15 in ...

Nov 17, 2017
popularity0 comments 0

Genomics-guided brain tumor treatment

Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment ...

Oct 26, 2017
popularity5 comments 0

Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting for 52% of all functional tissue brain tumor cases and 20% of all intracranial tumors. Despite being the most prevalent form of primary brain tumor, GBMs occur in only 2–3 cases per 100,000 people in Europe and North America. According to the WHO classification of the tumors of the central nervous system‎, the standard name for this brain tumor is "glioblastoma"; it presents two variants: giant cell glioblastoma and gliosarcoma. Glioblastomas are also an important brain tumor in canines, and research continues to use this as a model for developing treatments in humans.

Treatment can involve chemotherapy, radiation, radiosurgery, corticosteroids, antiangiogenic therapy, surgery and experimental approaches such as gene transfer.

With the exception of the brainstem gliomas, glioblastoma has the worst prognosis of any central nervous system (CNS) malignancy, despite multimodality treatment consisting of open craniotomy with surgical resection of as much of the tumor as possible, followed by concurrent or sequential chemoradiotherapy, antiangiogenic therapy with bevacizumab, gamma knife radiosurgery, and symptomatic management with corticosteroids. Prognosis is poor, with a median survival time of approximately 14 months.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Phone-addicted teens are unhappy, study finds

Happiness is not a warm phone, according to a new study exploring the link between adolescent life satisfaction and screen time. Teens whose eyes are habitually glued to their smartphones are markedly unhappier, said study ...

Group suggests pushing age of adolescence to 24

A small group of researchers with the Royal Children's Hospital in Australia is suggesting that it might be time to change the span of years that define adolescence—from the current 10 to 19 to a proposed 10 to 24 years ...